Pulmonary hypertension: therapeutic targets within the serotonin system.
about
Serotonylation of vascular proteins important to contractionA comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolitesEnhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetesVascular smooth muscle modulates endothelial control of vasoreactivity via reactive oxygen species production through myoendothelial communications.Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni').Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cellsSex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.The Xanthine Derivative KMUP-1 Attenuates Serotonin-Induced Vasoconstriction and K⁺-Channel Inhibitory Activity via the PKC Pathway in Pulmonary ArteriesEffects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.Functional constituents of a local serotonergic system, intrinsic to the human coronary artery smooth muscle cells.Long-term maternal hypoxia: the role of extracellular Ca2+ entry during serotonin-mediated contractility in fetal ovine pulmonary arteries.Regulation of allergic lung inflammation by endothelial cell transglutaminase 2.Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophanUse of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertensionDexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertensionThe importance of the gastrointestinal tract in the control of bone mass accrualVirodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product.Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteriesInhibitory effect of NBL1 on PDGF-BB-induced human PASMC proliferation through blockade of PDGFβ-p38MAPK pathway.Dexmedetomidine inhibits vasoconstriction via activation of endothelial nitric oxide synthase.Characterisation of Weibel-Palade body fusion by amperometry in endothelial cells reveals fusion pore dynamics and the effect of cholesterol on exocytosis.Nur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathwayFluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats.Treatment of pulmonary arterial hypertension with targeted therapies.The influence of gender on the development of pulmonary arterial hypertension.Evaluation of lorcaserin for the treatment of obesity.Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.Connexin-mediated regulation of the pulmonary vasculature.Novel Targets of Drug Treatment for Pulmonary Hypertension.In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension.PCPA protects against monocrotaline-induced pulmonary arterial remodeling in rats: potential roles of connective tissue growth factor.Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.MicroRNA-Dependent Control of Serotonin-Induced Pulmonary Arterial Contraction.Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice.
P2860
Q21562428-12A150E5-67CA-4DBA-910E-75A88846BA27Q27026643-5DFFEB65-D466-4E40-9C82-23A777F745E8Q27664075-1223EFCA-102C-468C-ACD1-7B9AEA393965Q28749389-DF369F06-44C4-441B-A190-B446FC36F865Q33489567-FBA6CBF0-3AB4-4017-B7C7-5742EACD07EDQ34027074-3EB31B38-AB80-4C65-9C7B-F005B80B4082Q34720232-858CFDE7-DA50-4341-82E3-F0FCD47C5112Q35262038-F965D193-F1D1-4C10-A422-43BB33CD81A3Q35632713-490E88FA-7D95-4A82-AB62-7671DB749C37Q35661148-53B789A6-5408-4CEB-A7E5-5E5F944FE043Q35864478-82EE6988-42FE-4896-B1B9-A00CBA695E92Q35931005-C879C344-4A9F-490D-8859-EA2F4EAEE82DQ36066483-CAE0F9BF-AE86-4568-A72F-4EBB85D94E18Q36312483-C45799A5-9085-44A2-A68A-AD71DC2A5BC6Q36411210-4FF93089-58DC-411C-9E8A-02C36E5B94CAQ36943390-AF2E69FC-87F9-4745-9342-F0930E5EC243Q36994142-F3E2D3FC-5CA4-40CC-828F-F02111D3E0B2Q37002393-595C4DCD-2F53-4A88-930A-A0AEE4DC38C2Q37077630-94CE200A-0895-4AB3-A219-1C1E511925E8Q37220791-C02B9A96-C3BA-438D-9C72-D8E478E316B8Q37239755-70E294B0-B2F9-498D-A05F-BA50A152E3DCQ37349128-A6CB6681-5E69-4FB6-B383-1419B40518A9Q37596153-069FBCBD-0D75-43FE-89BB-036183F20C33Q37720119-C2AB408B-5F94-48C1-A024-87BF6C7F179CQ37902509-A16AD777-3EB5-47F5-819A-D8BCE59F547BQ38102660-7B0AE7DA-A7CD-4011-BA47-F27916AF5CE7Q38117176-0D7ED322-C770-4352-A482-369EFBF0E534Q38219851-D79D072F-4D78-4E03-BDF1-75EC6C034539Q38502135-D71DC5AF-2EA8-4730-B08C-4EA02B9DE9C1Q38504399-28026EFE-891F-4306-B94F-2F6210319C57Q43279828-235B4C0A-17CD-472F-9297-8130DB39F495Q47562362-7C79917B-DF0E-4C96-8554-DE9038FE7BC8Q47755382-2807773B-5DC2-4CB3-8496-65B8AE6162BEQ47968330-E4885BCF-468C-49AD-8CB4-1DEF1E3FD1AFQ49975788-18AD99DE-C084-469F-9DDE-55215EE7EF13
P2860
Pulmonary hypertension: therapeutic targets within the serotonin system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulmonary hypertension: therapeutic targets within the serotonin system.
@en
Pulmonary hypertension: therapeutic targets within the serotonin system.
@nl
type
label
Pulmonary hypertension: therapeutic targets within the serotonin system.
@en
Pulmonary hypertension: therapeutic targets within the serotonin system.
@nl
prefLabel
Pulmonary hypertension: therapeutic targets within the serotonin system.
@en
Pulmonary hypertension: therapeutic targets within the serotonin system.
@nl
P2860
P921
P356
P1476
Pulmonary hypertension: therapeutic targets within the serotonin system
@en
P2093
M R MacLean
P2860
P304
P356
10.1038/BJP.2008.241
P407
P577
2008-06-09T00:00:00Z